Market Place
Sourcing Support
Menarini`s Obicetrapib Phase 3 Trial Positive For Familial Hypercholesterolemia
29 Jul 2024 //
PR NEWSWIRE
Menarini`s Prenatal Tech Detects Fetal Genomic Abnormalities From Blood Draw
02 Jul 2024 //
PR NEWSWIRE
Menarini Elacestrant Mbc Combos: Electra Elevate Updates Asco 2024
23 May 2024 //
BUSINESSWIRE
Docquity enables Italian biopharma company Menarini
20 Mar 2024 //
BIOSPECTRUM ASIA
Venatorx and Menarini Enter Agreement for Cefepime-Taniborbactam
09 Jan 2024 //
BUSINESSWIRE
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement
04 Jan 2024 //
BUSINESSWIRE
Menarini Presented Efficacy Data from Phase 1b/2 Combination Studies of ORSERDU
11 Dec 2023 //
PR NEWSWIRE
Menarini Presented Efficacy Data from Phase 1b/2 Studies of ORSERDU
11 Dec 2023 //
BUSINESSWIRE
Menarini Presents Progression-Free Survival Data from EMERALD Clinical Study
08 Dec 2023 //
BUSINESSWIRE
Menarini Group Announces New Data on ORSERDU® (elacestrant) at Symposium
21 Nov 2023 //
PR NEWSWIRE
Menarini Group Announces New Data on ORSERDU
20 Nov 2023 //
BUSINESSWIRE
Menarini and SciClone Pharma Announce Exclusive Sub-Licensing Collaboration
07 Nov 2023 //
BUSINESSWIRE
European Organisation for Research & Menarini Launch Trial in Breast Cancer
19 Oct 2023 //
PR NEWSWIRE
Lupin inks pact to acquire 5 drug brands from Menarini for Rs 101 crore
22 Sep 2023 //
ECONOMIC TIMES
Menarini`s Orserdu granted EU nod for advanced breast cancer
21 Sep 2023 //
BUSINESSWIRE
European Commission Approves Menarini Group’s ORSERDU® (Elacestrant)
20 Sep 2023 //
BUSINESSWIRE
Menarini Asia-Pacific Enters into Licensing Agreement with Astellas
12 Sep 2023 //
PR NEWSWIRE
The Menarini Group Announces ELZONRIS Designated as an Orphan Drug for BPDCN
30 Aug 2023 //
BUSINESSWIRE
Menarini Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU
21 Jul 2023 //
BUSINESSWIRE
Menarini Silicon announces the launch of its new CELLSEARCH® CTC test
13 Jul 2023 //
PR NEWSWIRE
Menarini`s Tenkasi (Oritavancin) Receives Approval in Europe
08 Jun 2023 //
EMA
Menarini Group Shares NEXPOVIO Subgroup Data from BOSTON trial
08 Jun 2023 //
PR NEWSWIRE
Early signals suggest oral SERD’s potential for more breast cancer patients
30 May 2023 //
PHARMACEUTICAL TECHNOLOGY
Menarini Shares Analysis from EMERALD Clinical Study of ORSERDU
26 May 2023 //
PR NEWSWIRE
Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU®
26 May 2023 //
PR NEWSWIRE
Menarini Group Announces New Data on Elacestrant at 2023 ESMO
09 May 2023 //
BUSINESSWIRE
Karyopharm and Menarini Group Receive Full Marketing Authorization for NEXPOVIO
21 Feb 2023 //
PR NEWSWIRE
Menarini gains first FDA approval for oral SERD in breast cancer
31 Jan 2023 //
FIERCE PHARMA
Guardant Health receives FDA approval for Guardant360 CDx
30 Jan 2023 //
BUSINESSWIRE
Carrick Therapeutics and Menarini to evaluate breast cancer combo therapy
20 Dec 2022 //
CLINICALTRIALSARENA
Carrick Therapeutics and Menarini to evaluate breast cancer combo therapy
20 Dec 2022 //
CLINICALTRIALSARENA
Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial
30 Nov 2022 //
PRNEWSWIRE
Menarini Presents Updated Results from Pivotal Ph3 EMERALD Trial at the 2022
30 Nov 2022 //
BUSINESSWIRE
QuantuMDx & Menarini Announce an Distribution Agreement for Q-POC Platform
03 Nov 2022 //
PRNEWSWIRE
QuantuMDx & Menarini Announce an Exclusive Distribution Agreement for the Q-POC™
01 Nov 2022 //
GLOBENEWSWIRE
Karyopharm & Menarini Announce Orphan Medicinal Designation for Selinexor
31 Oct 2022 //
PRESS RELEASE
Menarini and SciClone Sign Agreement to Develop and Commercialize Vaborem
21 Sep 2022 //
PRNEWSWIRE
As Sanofi`s SERD falls, Menarini’s advances with EU review
20 Aug 2022 //
FIERCEBIOTECH
Menarini`s Elacestrant MAA Accepted for Review by EMA
19 Aug 2022 //
BUSINESSWIRE
Menarini Group`s Elacestrant MAA Accepted for Review by EMA for Breast Cancer
19 Aug 2022 //
PRNEWSWIRE
Menarini`s filing for oral SERD elacestrant gets FDA priority review
12 Aug 2022 //
BUSINESSWIRE
Amid Roche and Sanofi`s oral SERD setbacks, Menarini gets speedy review at FDA
11 Aug 2022 //
ENDPOINTS NEWS
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA
11 Aug 2022 //
BUSINESSWIRE
Context Tx and Menarini Group Announce Trial Collaboration and Supply Agreement
02 Aug 2022 //
PRNEWSWIRE
Newamsterdam secures €1B-plus European commercial deal with Menarini
29 Jun 2022 //
BIOWORLD
Menarini Group and Radius Health Submit NDA to the U.S. FDA for Elacestrant
22 Jun 2022 //
PRNEWSWIRE
Menarini, Radius Health present analysis from elacestrant PIII trial at 2022
06 Jun 2022 //
PRNEWSWIRE
Menarini opens regional headquarters in Dubai Science Park
27 May 2022 //
BIOSPECTRUMASIA
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO in MM
20 May 2022 //
PRNEWSWIRE
Menarini, Radius Health publish elacestrant pivotal PIII EMERALD trial data
19 May 2022 //
PRNEWSWIRE
Karyopharm, Menarini Enter Exclusive License Agreement to Commercialize NEXPOVIO
21 Dec 2021 //
PRNEWSWIRE
Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703
04 Nov 2021 //
PRNEWSWIRE
Menarini, chased by 3 Big Pharmas, records breast cancer win
22 Oct 2021 //
FIERCEBIOTECH
A.Menarini soon to launch HA based dermal filler available with Lidocaine
21 Oct 2021 //
PHARMABIZ
Radius rockets higher as Kelly Martin boasts of a big PhIII success
21 Oct 2021 //
YAHOOFINANCE
Menarini introduces Definisse for use in minimally invasive medical procedures
14 Sep 2021 //
PHARMABIZ
Menarini to commercialize Japanese drug in Singapore, Malaysia, and Philippines
23 Aug 2021 //
BIOSPECTRUM ASIA
Menarini Group and Nippon Shinyaku Enter into an Exclusive License Agreement
29 Mar 2021 //
PRNEWSWIRE
Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp)
21 Jan 2021 //
PRNEWSWIRE
Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp)
21 Jan 2021 //
PRNEWSWIRE
